Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease

Keyphrases

• Alpha-synuclein (α-syn) 100%
• Small Molecules 100%
• Parkinson's Disease 100%
• Amyloid Aggregation 100%
• Rational Design 100%
• Neurodegenerative Diseases 50%
• Synaptic Proteins 50%
• Neurodegeneration 50%
• Rationally Designed 50%
• Effective Treatment 50%
• Highly Effective 50%
• Neurodegenerative Processes 50%
• New Therapeutics 50%
• In Silico 50%
• Amines 50%
• Therapeutic Tool 50%
• New Series 50%
• Binding Mode 50%
• Elderly Age 50%
• New Inhibitors 50%
• Docking Studies 50%
• Biological Assay 50%
• Aggregation Inhibitor 50%
• Toxic Oligomers 50%
• Pyridinyl 50%
• 1,2,4-Triazol 50%
• Disease-modifying Strategies 50%

Neuroscience

• Parkinson's Disease 100%
• Synuclein 100%
• Neurodegenerative Process 100%
• Oligomer 100%
• Alpha-Synuclein 100%
• Treatment of Parkinson's Disease 100%
• Neurodegenerative Disorder 100%
• Neurodegeneration 100%
• Amyloid Protein 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Parkinson's Disease 100%
• Synuclein 100%
• Amyloid Protein 100%
• Bioassay 50%
• Nerve Degeneration 50%
• Alpha Synuclein 50%
• Oligomer 50%